[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Phayao\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":76},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100649447","assessment-of-the-immunomodulatory-potential-of-spirulina-blue-protein-capsule-on-immunomodulation-in-healthy-volunteers-100649447",false,"NCT07733362","Assessment of the Immunomodulatory Potential of Spirulina Blue Protein Capsule on Immunomodulation in Healthy Volunteers","A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Immunomodulatory Potential and Safety of Spirulina Blue Protein Capsules in Healthy Volunteers","Inclusion Criteria:\n\n* Healthy male or female adults aged 25-60 years.\n* Body mass index (BMI) between 18.5 and 24.9 kg\u002Fm².\n* Able and willing to provide written informed consent.\n* Willing and able to comply with all study procedures and scheduled visits\n\nExclusion Criteria:\n\n* History of diseases affecting the immune system or metabolism, including cardiovascular disease, diabetes mellitus, liver disease, kidney disease, autoimmune disorders, or chronic inflammatory diseases.\n* Abnormal laboratory findings outside the reference range, including complete blood count, liver function tests, or renal function tests.\n* Current use of medications or dietary supplements that may affect the study outcomes.\n* Known allergy to Spirulina, algae-containing dietary supplements, or any component of the study capsules.\n* Pregnant or breastfeeding women.",true,"ALL","25 Years","60 Years",{"count":21,"type":22},54,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety and immunomodulatory effects of Spirulina Blue Protein capsules in healthy adults. Participants will be randomly assigned to receive placebo, 200 mg\u002Fday, or 1,000 mg\u002Fday of Spirulina Blue Protein capsules for 12 weeks. The study will assess changes in immune cell populations (CD4+, CD8+, and natural killer cells), circulating cytokine levels, hematological and biochemical parameters, and the occurrence of adverse events. The findings will provide evidence regarding the safety and potential immunomodulatory benefits of Spirulina Blue Protein supplementation in healthy individuals and support the development of evidence-based functional food and nutraceutical products.",[28,29],"Healthy Volunteers","Immune System",[31,32,28,33],"Immunomodulation","Spirulina Blue Protein","Immune Function","RECRUITING","2026-07-24",{"date":37,"type":38},"2026-07-29","ACTUAL",{"date":40,"type":22},"2026-08-15",{"date":42,"type":22},"2026-12-31",{"name":44,"class":45},"University of Phayao","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":19,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":46},"100611114","comparing-standard-dose-and-high-dose-cetirizine-for-acute-urticaria-100611114","NCT07236372","Comparing Standard-Dose and High-Dose Cetirizine for Acute Urticaria","Comparative Efficacy of Standard-Dose Versus Updosed Cetirizine in Acute Urticaria: A Randomized Controlled Trial","CURE-AU","Inclusion Criteria:\n\n* Adults aged 18 to 60 years\n* Clinical diagnosis of acute urticaria made by a physician\n* Onset of new wheals within the past 24 hours\n* Able and willing to comply with study procedures, complete symptom diaries, and attend follow-up visits\n* Provides written informed consent prior to participation\n\nExclusion Criteria:\n\n* Use of systemic corticosteroids within the past 5 days\n* Use of immunosuppressive medications within the past 5 days\n* Clinical signs of anaphylaxis, including respiratory distress, hypotension, abdominal pain, or acute laryngeal swelling\n* Presence of angioedema without wheals\n* Known diagnosis of chronic urticaria\n* Known severe renal impairment (creatinine clearance \\\u003C10 mL\u002Fmin), heart failure (ejection fraction \\\u003C40%), or hepatic failure\n* Other skin conditions that may interfere with assessment (e.g., atopic dermatitis, eczema, bullous pemphigoid, AGEP)\n* Use of ACE inhibitors or ARBs within the past 5 days\n* Known allergy or hypersensitivity to cetirizine or components of the study medication\n* Pregnancy or breastfeeding\n* Known diabetes mellitus\n* History of gastrointestinal ulcer disease\n* Any condition that, in the investigator's judgment, would interfere with study participation or safety\n* Declines to provide informed consent","18 Years",{"count":57,"type":22},140,[25],"The goal of this clinical trial is to learn whether a higher dose of cetirizine works better than the standard dose to relieve symptoms of acute urticaria (hives) in adults. The study also aims to learn about the safety of taking a higher dose for a short period of time. The main questions the study aims to answer are:\n\n1. Does the higher dose of cetirizine help people with acute urticaria improve faster than the standard dose?\n2. What side effects do participants experience when taking the higher dose?\n\nResearchers will compare two groups:\n\none group taking the standard dose of cetirizine (10 mg per day) and another group taking a higher dose (40 mg per day). This will help researchers understand which dose works better and whether the higher dose is safe.\n\nParticipants will:\n\nTake the assigned study medication for 7 days Record their daily symptoms, including itch and hive severity Return for follow-up visits on Day 3, Day 7, and Week 6 Have blood tests to check liver and kidney function before and after treatment\n\nThis study may help improve treatment options for people with acute urticaria and reduce the need for unnecessary steroid use.",[61],"Acute Urticaria",[61,63,64,65,66,67],"Updosed Cetirizine","High-Dose Antihistamine","Standard-Dose Cetirizine","Second-Generation Antihistamine","Randomized Controlled Trial","2026-05-31",{"date":70,"type":38},"2026-06-03",{"date":72,"type":38},"2025-11-15",{"date":74,"type":22},"2026-10",{"name":44,"class":45},""]